AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
BioLineRX Ltd
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001Y26MC7
2.04▼ 0.02 (-1.14%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
2.06
Day's Range
2.04 – 2.11
52-Week Range
1.95 – 3.95
Volume
1,703
Avg Volume
14.8K
Share Statistics
Shares Outstanding
Employees
24
Exchange
XNAS
Listed
2011-07-25
Share count as of March 8, 2026

BioLineRX Ltd (BLRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about BioLineRX Ltd (BLRX)
What is BioLineRX Ltd's Market Cap?
BioLineRX Ltd's Market Cap is $5.3B, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's Enterprise Value?
BioLineRX Ltd's Enterprise Value is $5.3B, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's Price / Sales?
BioLineRX Ltd's Price / Sales is 3826.2×, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's EV / Revenue?
BioLineRX Ltd's EV / Revenue is 3816.8×, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's EV / EBITDA?
BioLineRX Ltd's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's Revenue (TTM)?
BioLineRX Ltd's Revenue (TTM) is $1.4M, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's Net Income (TTM)?
BioLineRX Ltd's Net Income (TTM) is -$10.1M, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's EBITDA?
BioLineRX Ltd's EBITDA is -$11.7M, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's Diluted EPS (TTM)?
BioLineRX Ltd's Diluted EPS (TTM) is -0.00, based on as-reported figures from SEC (XBRL) filings.
What is BioLineRX Ltd's EBITDA Margin?
BioLineRX Ltd's EBITDA Margin is -838.7%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BLRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Jun 30, 2025
Profit or loss [abstract]
ROYALTY REVENUES
COST OF REVENUES
GROSS PROFIT
RESEARCH AND DEVELOPMENT EXPENSES
GENERAL AND ADMINISTRATIVE EXPENSES
OPERATING LOSS
NON-OPERATING INCOME (EXPENSES), NET
Interest Income
FINANCIAL EXPENSES
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)
EARNINGS (LOSS) PER ORDINARY SHARE – BASIC ATTRIBUTABLE TO OWNERS OF THE COMPANY
EARNINGS (LOSS) PER ORDINARY SHARE – DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY